I finished my psychiatry residency in 1977 and was in psychoanalytic training traveling between Atlanta and New York biweekly and busy enough for several people, so I was barely aware of the DSM-III Revision that would have such an impact. After it came out, people spoke of little else, and I never got it. So […]
from: DSM-5 Critics Pump Up the Volume MedPage Today By John Gever February 29, 2012 DSM-5 Leaders Stand Their Ground In a conversation with MedPage Today, APA President John Oldham, MD, and DSM-5 task force chairman David Kupfer, MD, defended their handling of the revision and argued that many of the criticisms were off-base. For […]
A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations with Industry: A Pernicious Problem Persists PLoS Medicine by Lisa Cosgrove and Sheldon Krimsky March 13, 2012 Summary Points The American Psychiatric Association (APA) instituted a financial conflict of interest disclosure policy for the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders […]
Despite Recalls, Legal Settlements and Guilty Pleas – A $143.5 Million (or Perhaps $197 Million) Golden Parachute for the Former Drug Represenative Who Is Now CEO of Johnson and Johnson Healthcare Renewal by Roy Poses March 15, 2012 After 30 separate product recalls since 2009, and multiple legal settlements and guilty pleas, we noted that […]
Looking over the Texas Trial transcripts in the last post reminded me of something. I have no experience with the law or lawyering except for giving a few depositions. I’ve never made it to the stand, cases always settling before it came to that [to my great relief]. So this first part mostly went over […]
J&J Said to Face Demand to Lift Risperdal Settlement Offer by $800 Million Bloomberg By Margaret Cronin Fisk, Jef Feeley and David Voreacos March 12, 2012 Johnson & Johnson faces a U.S. government demand to raise its offer by $800 million from an initial proposal to settle a federal civil investigation into marketing of the […]
On February 29th, I said I smell a campaign… I take no joy in having been right about that. I thought it was a Lilly [Cymbalta] and Pfizer [Pristiq] show, but I see Forest Laboratories [Viibryd] has joined in the mix [sponsoring the Emslie/Gibbons Medscape C.M.E.]. Looking over the list of authors in that Journal […]
Journal of Child and Adolescent Psychopharmacology Special Issue on Psychopharmacology of Adolescent Depression Guest Editor: G.J. Emslie, MDFREE ISSUE Editorial Adolescent Depression Harold S. Koplewicz Guest Editorial The Psychopharmacology of Adolescent Depression< Graham J. Emslie Original Articles Out of the Black Box: Treatment of Resistant Depression in Adolescents and the Antidepressant Controversy Karen Dineen Wagner, […]
I ended my last post by saying I’d "go rest a while" – but it wasn’t as restful as I’d planned. Ever since the second Gibbons article came out [Benefits From Antidepressants], I’ve had a nagging doubt about the outcome, particularly in children. The reported response rates and remission rates just seem too good to […]
In June 2009, the Institute of Medicine held a Workshop in Washington DC, CNS CLINICAL TRIAL: SUICIDALITY AND DATA COLLECTION [available on-line]. It was sponsored by an array of foundations and pharmaceutical companies, co-chaired by Dr. William Potter of Merck Research Laboratories and Dr. Robert Gibbons of the University of Illinois at Chicago. The topic […]